Excess body weight is a global health problem due to sedentary lifestyle and unhealthy diet,
affecting 2 billion population worldwide. Obesity is a major risk factor for metabolic diseases …

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing
need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Abstract Background A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-
like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug …

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like
peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle …

Importance The effect of continued treatment with tirzepatide on maintaining initial weight
reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical …

Background Weight reduction is essential for improving health outcomes in people with
obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Importance Metabolic surgery leads to weight loss and improved health, but these outcomes
are highly variable. Poor weight loss is associated with lower circulating levels of glucagon …

Obesity is a chronic, progressive and relapsing disease with a rising global prevalence
associated with increased morbidity and mortality and reduced quality of life. Treatment of …